Valiant Laboratories Limited has scheduled a meeting of its Board of Directors for Monday, August 10, 2026. The primary agenda of this meeting is to consider and approve both the Standalone and Consolidated Audited Financial Results for the quarter ended June 30, 2026 (Q1 FY27).
This intimation is formally made pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
In accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015 and the company's internal Code of Conduct, the Trading Window for dealing in the company's securities was previously closed effective June 26, 2026. The window is mandated to remain closed until August 12, 2026, which is 48 hours after the financial results are declared.
This disclosure has also been uploaded to the company's official website at www.valiantlabs.in.
The letter is signed by Akshay Gangurde, who holds the positions of Company Secretary and Compliance Officer.